News coverage about Ophthotech Corporation (NASDAQ:OPHT) has trended somewhat positive on Monday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ophthotech Corporation earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.9935011987251 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s analysis:

Several brokerages recently commented on OPHT. ValuEngine upgraded Ophthotech Corporation from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 target price on shares of Ophthotech Corporation in a report on Thursday, September 21st. Finally, Zacks Investment Research upgraded Ophthotech Corporation from a “hold” rating to a “strong-buy” rating and set a $3.25 target price on the stock in a report on Monday, November 13th. Twelve investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $8.31.

Shares of Ophthotech Corporation (OPHT) opened at $3.35 on Monday. Ophthotech Corporation has a twelve month low of $2.24 and a twelve month high of $40.34. The company has a market capitalization of $120.73, a P/E ratio of 2.13 and a beta of 1.40.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Ophthotech Corporation (OPHT) Share Price” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at

About Ophthotech Corporation

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech Corporation (NASDAQ:OPHT)

Receive News & Stock Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related stocks with our FREE daily email newsletter.